Clinical trial NCT06047158: Effects of Omega-3 Fish Oil Fat Emulsion on Rehabilitation and Immune Function After Radical Surgery Combined With Intraperitoneal Hyperthermic Infusion Chemotherapy in Patients With Locally Advanced Gastric Cancer
Official title: Effects of Omega-3 Fish Oil Fat Emulsion on Rehabilitation and Immune Function After Radical Surgery Combined With Intraperitoneal Hyperthermic Infusion Chemotherapy in Patients With Locally Advanced Gastric Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Fish Oils
Perfusion; Complications
Stomach Neoplasms
Nutrition Aspect of Cancer
Chemotherapy Effect
Immunisation Reaction
Lead sponsor: The Affiliated Hospital of Qingdao University
Sponsor class: OTHER
First posted: 2023-09-21
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population were patients with advanced gastric cancer who had received surgical treatment. According to the wishes of the patients, they chose whether to use omega-3 fish oil fat emulsion and were assigned to different groups to observe the effect.

Brief summary: The purpose of this study was to investigate the effects of omega-3 fish oil fat emulsion on peripheral blood C-reactive protein, total lymphocyte count, plasma albumin and immune function after radical surgery combined with intraperitoneal hyperthermic perfusion chemotherapy in patients with locally advanced gastric cancer. at the same time, to explore the effects of omega-3 fish oil fat emulsion on complications, length of stay and total cost of hospitalization.

The main question it aims to answer is whether the use of omega-3 fish oil fat emulsion can improve patients' immunity, speed up recovery and reduce costs.

Participants will comprehensively collect patient-related baseline data, including sex, age, BMI, ASA grade, tumor location, histological grade, pathological tumor type, pTNM stage (AJCC cancer stage 8), and perilymphatic vascular / nerve infiltration.

Immune function evaluation related index: peripheral blood lymphocyte count. Plasma albumin concentration, C-reactive protein, postoperative infectious complications, length of stay and cost of hospitalization.

Finally, statistical analysis software was used to analyze the differences between the two groups, evaluate the above indicators and draw mutual conclusions.

Detailed description: The research process is as follows:

1. Select patients in the group according to the inclusion and exclusion criteria.
2. The patient signed the informed consent form
3. His system was used to collect patient data, including human-related baseline data, including sex, age, BMI, ASA grade, tumor location, histological grade, pathological tumor type, pTNM stage (AJCC cancer stage 8th edition), lymphatic vascular / nerve infiltration. Immune function evaluation related index: peripheral blood lymphocyte count. Plasma albumin concentration, C-reactive protein, postoperative infectious complications, length of stay and cost of hospitalization.
4. Using statistical software (SPSS) to judge the statistical difference.
5. It is concluded that the use value of omega-3 fish oil fat emulsion (Ewing) is evaluated.

Eligibility criteria: Inclusion Criteria:

* The age is 18 to 75 years old.
* For advanced gastric cancer, according to the TNM staging specified by the 8th edition AJCC, the clinical staging or EUS staging is above T2. There is no distant metastasis before operation, and the tumor does not directly invade the surrounding organs (liver, pancreas, spleen and transverse mesocolon, etc.).
* There is no obvious contraindication to surgery.
* The preoperative physical status score of Eastern American Cancer Cooperation (ECOG) was 0 or 1.
* The preoperative ASA grade was grade Ⅰ-Ⅲ.
* No previous history of gastric surgery, no history of other malignant tumors.
* After explaining the nature and purpose of the study, agree to sign an informed consent form, give voluntary consent to participate in the study, and comply with the requirements of the study.

Exclusion Criteria:

* Radiotherapy or chemotherapy before operation.
* Use of immunosuppressants such as hormones within 3 months before treatment.
* Preoperative anemia (hemoglobin \< 90g/L) and severe hypoalbuminemia (albumin \< 30g/L).
* With severe heart and lung and other important organ dysfunction.
* More serious metabolic and immune diseases, such as hyperthyroidism, poor blood glucose control in diabetes, obesity, hyperlipidemia (triglyceride \> 3mmol/L, total bile solid \> 6.2mmol/L).
* Severe infection before operation.
* With complete intestinal obstruction, intestinal perforation and intestinal necrosis.
* During the operation, it was found that radical operation could not be performed or combined organ resection was needed.
* Operation time \> 6 hours, intraoperative bleeding \> 400ml

Primary outcomes:
measure: Immune related index
timeFrame: one week
measure: Immune related index
timeFrame: one week
measure: Immune related index
timeFrame: one week
measure: Immune related index
timeFrame: one week
Secondary outcomes:
measure: Hospitalization related
timeFrame: From the first day after operation to discharge, up to 30 days.
measure: Hospitalization related
timeFrame: From the first day after operation to discharge, up to 30 days.
Other outcomes:
Locations:
city: Qingdao
country: China
facility: Ruiqing Liu
state: Shan Dong
Study officials:
References: